R&D channel feed

Bio­gen shut­ters a biotech shop in the UK as it con­tin­ues to prune R&D

9 years ago
Pharma

Play­ing catch-up, Eli Lil­ly is hus­tling pos­i­tive PhI­II CGRP mi­graine da­ta to the FDA as late-stage ri­val­ry heats up

9 years ago

Arde­lyx rolls out pos­i­tive PhI­II IBS-C da­ta on tena­panor as ri­vals prep for a show­down, but shares crater

9 years ago

As­traZeneca’s shares spike on a sur­prise coup in PhI­II lung can­cer da­ta

9 years ago

Reg­u­la­tors or­der AB Sci­ence to halt tri­al work on PhI­II ALS drug, de­mand­ing proof it's cleaned up

9 years ago
Pharma

Ar­ray shares surge as sec­ond chap­ter of its PhI­II can­cer com­bo sto­ry ends on an up­beat note

9 years ago

As­traZeneca’s PhI­II bid on asth­ma drug tralok­inum­ab flops, and that’s no sur­prise

9 years ago

In a stun­ning set­back, Roche says its top can­cer drug Tecen­triq failed a key PhI­II study

9 years ago

PhRMA drums out 22 mem­bers who didn’t make the cut as ma­jor league R&D play­ers

9 years ago
Pharma

Syn­er­gy Phar­ma preps step 2 for Tru­lance as pos­i­tive PhI­II IBS-C da­ta squares off against Iron­wood and Arde­lyx

9 years ago

Re­cro Phar­ma tees up an NDA for its COX-2 pain drug fol­low­ing pos­i­tive PhI­II pro­gram

9 years ago

One of Kite Phar­ma’s CAR-T pa­tients died from cere­bral ede­ma, trig­ger­ing a safe­ty alarm

9 years ago

On­coMed racks up three straight clin­i­cal dis­as­ters as lead drug im­plodes

9 years ago

Vivek Ra­maswamy’s My­ovant out­lines the PhII case for its lead drug, now in a late-stage test

9 years ago

Trou­bled Teva's suc­ces­sor to Co­pax­one just failed a big PhI­II test for mul­ti­ple scle­ro­sis

9 years ago

Stuck on FDA hold, Reg­u­lus CEO hits the ex­it as re­or­ga­ni­za­tion slash­es staff at the be­lea­guered biotech

9 years ago
Pharma

Zaf­gen stakes out a PhI beach­head for its next weight drug as it fights for a come­back

9 years ago

No­var­tis con­tin­ues its blitz on NASH deals, grab­bing an ex­clu­sive tie-up in race to de­vel­op cock­tails

9 years ago
Pharma

De­fy­ing the odds, Pox­el plots a PhI­II course for its Type 2 di­a­betes med and shares surge on new da­ta

9 years ago

Quin­tiles­IMS an­a­lysts fore­cast a wave of new drug ap­provals by '22, dom­i­nat­ed by can­cer and or­phan ther­a­pies

9 years ago
Pharma

As­traZeneca com­mits $57.5M to seed An­ti­calin R&D pact with Pieris, a biotech on a roll

9 years ago
Pharma

No­var­tis takes the long view on CAR-T, grab­bing li­cens­es on new tech for next-gen ther­a­pies

9 years ago

Pfiz­er dumps a failed PhII Hunt­ing­ton’s drug in lat­est pipeline prun­ing

9 years ago

Hit-and-miss PhI­I­Is leave Lund­beck and Ot­su­ka’s lat­est Alzheimer’s pro­gram in a pre­car­i­ous po­si­tion

9 years ago
First page Previous page 300301302303304305306 Next page Last page
A service from the Financial Times